Urokinase receptor and fibronectin regulate the ERK(MAPK) to p38(MAPK) activity ratios that determine carcinoma cell proliferation or dormancy in vivo.
about
Tumor dormancy: potential therapeutic target in tumor recurrence and metastasis preventionERp29 induces breast cancer cell growth arrest and survival through modulation of activation of p38 and upregulation of ER stress protein p58IPKConstitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosisβ1 and β4 integrins: from breast development to clinical practiceMechanisms of disseminated cancer cell dormancy: an awakening fieldCancer Cell Colonisation in the Bone MicroenvironmentTumor cell dormancyMetastatic colonization by circulating tumour cellsMaspin inhibits cell migration in the absence of protease inhibitory activityTumor-vascular interactions and tumor dormancyA link between inflammation and metastasis: serum amyloid A1 and A3 induce metastasis, and are targets of metastasis-inducing S100A4Computer aided identification of small molecules disrupting uPAR/alpha5beta1--integrin interaction: a new paradigm for metastasis preventionVersican G3 domain modulates breast cancer cell apoptosis: a mechanism for breast cancer cell response to chemotherapy and EGFR therapyRap1GAP inhibits tumor growth in oropharyngeal squamous cell carcinomaErythropoietin promotes Schwann cell migration and assembly of the provisional extracellular matrix by recruiting beta1 integrin to the cell surfaceThe low density lipoprotein receptor-related protein mediates fibronectin catabolism and inhibits fibronectin accumulation on cell surfaces.Validation of a device for the active manipulation of the tumor microenvironment during intravital imaging.The Kruppel-like KLF4 transcription factor, a novel regulator of urokinase receptor expression, drives synthesis of this binding site in colonic crypt luminal surface epithelial cells.Ribonomic and short hairpin RNA gene silencing methods to explore functional gene programs associated with tumor growth arrest.Tamoxifen induces pleiotrophic changes in mammary stroma resulting in extracellular matrix that suppresses transformed phenotypesThe urokinase receptor (u-PAR)--a link between tumor cell dormancy and minimal residual disease in bone marrow?Versican G3 promotes mouse mammary tumor cell growth, migration, and metastasis by influencing EGF receptor signaling.Extracellular matrix: a gatekeeper in the transition from dormancy to metastatic growthCleaved high-molecular-weight kininogen and its domain 5 inhibit migration and invasion of human prostate cancer cells through the epidermal growth factor receptor pathwayMolecular pathways: niches in metastatic dormancyAnalysis of marker-defined HNSCC subpopulations reveals a dynamic regulation of tumor initiating properties.Functional convergence of signalling by GPI-anchored and anchorless forms of a salamander protein implicated in limb regeneration.Urokinase upregulates matrix metalloproteinase-9 expression in THP-1 monocytes via gene transcription and protein synthesisCoordinate regulation of fibronectin matrix assembly by the plasminogen activator system and vitronectin in human osteosarcoma cells.The Unfolded Protein Response, Degradation from Endoplasmic Reticulum and CancerSPRY1 promotes the degradation of uPAR and inhibits uPAR-mediated cell adhesion and proliferationBreast cancer at bone metastatic sites: recent discoveries and treatment targets.A urokinase receptor-Bim signaling axis emerges during EGFR inhibitor resistance in mutant EGFR glioblastoma.Evaluation of proliferation and apoptosis markers in circulating tumor cells of women with early breast cancer who are candidates for tumor dormancy.NR2F1 controls tumour cell dormancy via SOX9- and RARβ-driven quiescence programmes.Controversies in clinical cancer dormancyMechanisms governing metastatic dormancy and reactivation.Cytokine-induced monocyte MMP-1 is negatively regulated by GSK-3 through a p38 MAPK-mediated decrease in ERK1/2 MAPK activation.A new class of orthosteric uPAR·uPA small-molecule antagonists are allosteric inhibitors of the uPAR·vitronectin interactionp38α Signaling Induces Anoikis and Lumen Formation During Mammary Morphogenesis.
P2860
Q21195742-5F020699-E3AD-42F5-8718-2CD1FC1E7590Q24296295-3FF16410-EFA5-4592-B6FA-65B06EA97D01Q24791830-CD483681-3EAC-44D0-9424-729C31726379Q27000311-733A2B71-DB09-4453-AD3B-B012F8F0A611Q27027015-F9EDA3B7-1DD4-4173-A365-BE9BEF8A0323Q28072561-CDBB43C5-B187-4E81-94FE-8EDA560D4401Q28073065-E9FE5F68-1DF9-48C6-B21A-DC6C084F20FEQ28076164-86AF8F74-DF45-4D3C-BC74-BB39C0F9AB5FQ28207990-7250F455-3D22-489C-BD75-8FB71FAB97B0Q28295975-2C8CDDA5-F80A-4CA9-ACEF-17C0783BF981Q28306743-B6B1F180-2C6E-4F5D-8F7F-569B05AEE0AAQ28474854-7A03DA5A-16BD-4B5F-9C6F-B3F1F36D2500Q28477876-92728922-C371-4162-978E-C47BC575BCFFQ28579227-0185D6B1-2DEF-40E9-AD3C-0CA08C1A3A3DQ28580949-F2C0FB50-1856-4AD8-8E26-58A0218E8637Q30308805-38F7D6EB-D2B0-4325-A874-C1F0FE6C99FBQ30826467-06B9AC00-CD65-4A5F-9264-09DBEC3452A6Q33199829-C458E208-80EA-46B0-9B6F-A2F46BB52889Q33316344-B49BF036-0CAF-4EF4-91CA-93A7A3A627AFQ33403396-B807E552-EE21-4969-8293-5C8E43A39F19Q33649574-F4C0C411-F294-40B2-B084-7EA444CE3726Q33747782-1BB51F85-248A-49A9-A0FD-02858995B542Q33798648-0BC99331-58DB-4B0F-8D2B-8D864F0C0CDEQ33816577-39D889F7-C9A9-4FE1-9264-C61C7ACBA10DQ33838536-46C2964F-E274-481E-972D-E13636499C1AQ34140296-CECB3FAF-EB65-4BB5-A12C-4C8541610020Q34152526-D617DE6B-7853-4BD2-B0B6-DCD8B2039702Q34525272-263ECEF3-68EE-42CA-BAC0-E3BF136F0A87Q34567465-A5A8E782-E624-4F06-ABC7-D13852F47957Q34576070-8C4650B3-F4DA-4D23-9B18-2BF373597BB5Q34704836-ADEDDF93-26C0-4B81-A382-D2305F5115FCQ34939979-B62D3E90-8D36-4A24-AF92-2220D904EC29Q34979703-4B2643F4-73B6-4D74-A7A3-0CFE78F15AECQ35000713-9DCE339B-B69B-424E-AF2F-9276DF67A74AQ35037151-192F95B4-6028-4E6E-A8A8-37B0994C4B0CQ35134139-70DF151A-1BBA-4E5F-A353-9B06C645FDB0Q35162521-CCC3CA2E-37DA-4404-B5C8-5FDED4480F18Q35430731-79802503-0E1A-4364-90F2-AEAB9F9F23C2Q35559411-715244ED-5EDE-4050-A5E7-AAAF214143B9Q35588465-58E7B487-EB75-45C2-B269-30B9A64646B9
P2860
Urokinase receptor and fibronectin regulate the ERK(MAPK) to p38(MAPK) activity ratios that determine carcinoma cell proliferation or dormancy in vivo.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
2001年论文
@zh
2001年论文
@zh-cn
name
Urokinase receptor and fibrone ...... iferation or dormancy in vivo.
@ast
Urokinase receptor and fibrone ...... iferation or dormancy in vivo.
@en
type
label
Urokinase receptor and fibrone ...... iferation or dormancy in vivo.
@ast
Urokinase receptor and fibrone ...... iferation or dormancy in vivo.
@en
prefLabel
Urokinase receptor and fibrone ...... iferation or dormancy in vivo.
@ast
Urokinase receptor and fibrone ...... iferation or dormancy in vivo.
@en
P2093
P2860
P356
P1476
Urokinase receptor and fibrone ...... liferation or dormancy in vivo
@en
P2093
P2860
P304
P356
10.1091/MBC.12.4.863
P577
2001-04-01T00:00:00Z